Crosswire — October 06, 2026

DAILY BRIEFING --- SCIENCE & MEDICINE Optogenetics Wins the Nobel — and It's a Genuine Landmark What changed: The Nobel Prize in Physiology or Medicine goes to American psychiatrist-neurologist Karl Deisseroth and German researchers Peter Hegemann and Georg Nagel for founding optogenetics. Hegemann and Nagel identified channelrhodopsin — a light-sensitive protein from algae — in the early 2000s; Deisseroth figured out how to insert it into neurons and switch them on and off with light. Prize: 12 million Swedish kronor (~£900,000), split three ways. Why it matters: This is the tool that turned "which brain region does X" into "which specific circuit does X, and what happens if I fire it right now." It lets researchers activate or silence individual neural circuits in animals — triggering memories, feelings, and behaviours on demand. That's the mechanistic foundation under a lot of modern psychiatric and neurological research, and it's now extending into how the nervous system talks to the heart and gut. What to watch: Clinical translation is still early and narrow. The most advanced human application is a trial using optogenetics to partially restore vision in retinitis pigmentosa patients — a light-sensitive protein is inserted into the damaged eye and driven by light-emitting glasses. That's a real trial, not a product. Don't expect optogenetic therapies for brain disorders on any near-term timeline; the animal work is transformative, the human work is embryonic. --- Note: No geopolitics or tech/AI items cleared the bar for inclusion today — the source material carried only the Nobel announcement. Rather than pad the briefing, I'm flagging it. Back tomorrow with the full spread.